Sort   by:  
 Page size 
ProteomicsDifferential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology: Phosphoproteomics
Multiple tyrosine kinase inhibitors (TKIs) are often developed for the same indication. However, their relative overall efficacy is frequently incompletely understood and they may harbor unrecognized targets that cooperate with the intended target. We compared several ROS1 TKIs for inhibition of ROS...
ORGANISM(S): Homo sapiens (Human) 
2024-04-05 | PXD031359 | Pride
Polypharmacology Tyrosine kinase inhibitors Phosphoproteomics Ros1 Lung cancer Lorlatinib 
UnknownMedicinal Polypharmacology in the Clinic - Translating the Polypharmacolome into Therapeutic Benefit.
Not available
S-EPMC10927880 | biostudies-literature
ProteomicsDifferential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology: Phosphotyrosine Profiling
Multiple tyrosine kinase inhibitors (TKIs) are often developed for the same indication. However, their relative overall efficacy is frequently incompletely understood and they may harbor unrecognized targets that cooperate with the intended target. We compared several ROS1 TKIs for inhibition of ROS...
ORGANISM(S): Homo sapiens (Human) 
2024-04-05 | PXD031346 | Pride
Polypharmacology Tyrosine kinase inhibitors Phosphotyrosine Ros1 Lung cancer Lorlatinib 
ProteomicsDifferential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology: Chemical Proteomics
Multiple tyrosine kinase inhibitors (TKIs) are often developed for the same indication. However, their relative overall efficacy is frequently incompletely understood and they may harbor unrecognized targets that cooperate with the intended target. We compared several ROS1 TKIs for inhibition of ROS...
ORGANISM(S): Homo sapiens (Human) 
2024-04-05 | PXD031690 | Pride
Polypharmacology Tyrosine kinase inhibitors Chemical proteomics Ros1 Lung cancer Lorlatinib 
ProteomicsDivergent polypharmacology-driven cellular activity of structurally similar multi-kinase inhibitors through cumulative differential effects on individual targets: ABPP
Despite recent successes of precision and immunotherapies there is a persisting need for novel targeted or multi-targeted approaches in complex diseases. Through a systems pharmacology approach including phenotypic screening, chemical and phosphoproteomics and RNA-Seq, we elucidated the targets and ...
ORGANISM(S): Homo sapiens (Human) 
2020-07-07 | PXD012965 | Pride
Abpp Cabozantinib Polypharmacology Foretinib Lung cancer 
UnknownAdvances in Computational Polypharmacology.
Not available
S-EPMC10078381 | biostudies-literature
UnknownPolypharmacology in Precision Oncology: Current Applications and Future Prospects.
Not available
S-EPMC5403974 | biostudies-literature
UnknownPrivileged Structures and Polypharmacology within and between Protein Families.
Not available
S-EPMC6295861 | biostudies-literature
GenomicsExploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders
Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders
PRJNA1276571 | ENA
UnknownEvolution of kinase polypharmacology across HSP90 drug discovery.
Not available
S-EPMC8550792 | biostudies-literature
Sort   by:  
 Page size